Filtered By:
Condition: Hemorrhagic Stroke
Drug: Activase

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 351 results found since Jan 2013.

Intravenous Thrombolysis for Stroke Recurring Within 3 Months From the Previous Event Clinical Sciences
Conclusions— Patients currently treated with alteplase, despite a history of previous stroke ≤3 months, do not seem to achieve worse outcome than those with first-ever stroke. Although careful patient selection was probably of major importance, our findings provide reassurance that this group of patients may safely benefit from thrombolysis and should not be arbitrarily excluded as a whole. Further studies are needed to identify the shortest safe time lapse from the previous event to treatment with alteplase.
Source: Stroke - October 26, 2015 Category: Neurology Authors: Karlinski, M., Kobayashi, A., Czlonkowska, A., Mikulik, R., Vaclavik, D., Brozman, M., Gdovinova, Z., Švigelj, V., Csiba, L., Fekete, K., Korv, J., Demarin, V., Bašic-Kes, V., Vilionskis, A., Jatuzis, D., Krespi, Y., Shamalov, N., Andonova, Tags: Emergency treatment of Stroke, Thrombolysis Clinical Sciences Source Type: research

Intravenous Thrombolysis in Unknown-Onset Stroke Clinical Sciences
Conclusions—Our data suggest no excess risk of symptomatic intracerebral hemorrhage but increased mortality and reduced favorable outcome in patients with UKO stroke compared with patients treated within the approved time window.
Source: Stroke - February 26, 2017 Category: Neurology Authors: Laura Dorado, Niaz Ahmed, Gotz Thomalla, Manuel Lozano, Branko Maloȷcic, Mushtaq Wani, Monica Millan, Ales Tomek, Antoni Davalos Tags: Cerebrovascular Disease/Stroke, Ischemic Stroke Original Contributions Source Type: research

Novel Telestroke Program Improves Thrombolysis for Acute Stroke Across 21 Hospitals of an Integrated Healthcare System Clinical Sciences
This study included 310 patients treated with alteplase in the pre–EXpediting the PRrocess of Evaluating and Stopping Stroke period and 557 patients treated with alteplase in the EXpediting the PRrocess of Evaluating and Stopping Stroke period. After implementation, alteplase administrations increased to 62/mo from 34/mo at baseline (P
Source: Stroke - December 22, 2017 Category: Neurology Authors: Mai N. Nguyen-Huynh, Jeffrey G. Klingman, Andrew L. Avins, Vivek A. Rao, Abigail Eaton, Sunil Bhopale, Anne C. Kim, John W. Morehouse, Alexander C. Flint Tags: Treatment, Cerebrovascular Disease/Stroke, Ischemic Stroke Original Contributions Source Type: research

Acute Reperfusion Therapy and Stroke Care in Asia After Successful Endovascular Trials Understanding and Applying the Endovascular Trials
The current status of and prospects for acute stroke care in Asia in the situation where both intravenous thrombolysis and endovascular therapies have been recognized as established strategies for acute stroke are reviewed. Of 15 million people annually having stroke worldwide, 9 million are Asians. The burdens of both ischemic and hemorrhagic strokes are severe in Asia. The unique features of stroke in Asia include susceptibility to intracranial atherosclerosis, high prevalence of intracerebral hemorrhage, effects of dietary and lifestyle habits, and several disorders with genetic causes. These features affect acute strok...
Source: Stroke - May 22, 2015 Category: Neurology Authors: Toyoda, K., Koga, M., Hayakawa, M., Yamagami, H. Tags: Emergency treatment of Stroke, Anticoagulants, Thrombolysis, Angioplasty and Stenting Understanding and Applying the Endovascular Trials Source Type: research

Uric Acid Therapy Prevents Early Ischemic Stroke Progression Brief Report
Conclusions—UA therapy may prevent EIW after acute stroke in thrombolysed patients. Optimal access of UA to its molecular targets through appropriate collaterals may modify the magnitude of the neuroprotective effect.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00860366.
Source: Stroke - October 23, 2016 Category: Neurology Authors: Amaro, S., Laredo, C., Renu, A., Llull, L., Rudilosso, S., Obach, V., Urra, X., Planas, A. M., Chamorro, A. Tags: Cerebrovascular Disease/Stroke, Ischemic Stroke, Neuroprotectants Brief Reports Source Type: research

Clinical Utility of Electronic Alberta Stroke Program Early Computed Tomography Score Software in the ENCHANTED Trial Database Clinical Sciences
Background and Purpose—Clinical utility of electronic Alberta Stroke Program Early CT Score (e-ASPECTS), an automated system for quantifying signs of infarction, was evaluated in a large database of thrombolyzed patients with acute ischemic stroke.Methods—All baseline noncontrast computed tomographic scans of patients with anterior circulation acute ischemic stroke who participated in the alteplase dose arm of the randomized controlled trial ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) were reviewed; poor quality and large (>6 mm) slice thickness were excluded. Included scans had e-ASPECTS...
Source: Stroke - May 25, 2018 Category: Neurology Authors: Simon Nagel, Xia Wang, Cheryl Carcel, Thompson Robinson, Richard I. Lindley, John Chalmers, Craig S. Anderson Tags: Cerebrovascular Disease/Stroke, Ischemic Stroke Original Contributions Source Type: research

Remote Ischemic Perconditioning as an Adjunct Therapy to Thrombolysis in Patients With Acute Ischemic Stroke: A Randomized Trial Clinical Sciences
Conclusions— Although the overall results were neutral, a tissue survival analysis suggests that prehospital rPerC may have immediate neuroprotective effects. Future clinical trials should take such immediate effects, and their duration, into account. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00975962.
Source: Stroke - December 23, 2013 Category: Neurology Authors: Hougaard, K. D., Hjort, N., Zeidler, D., Sorensen, L., Norgaard, A., Hansen, T. M., von Weitzel-Mudersbach, P., Simonsen, C. Z., Damgaard, D., Gottrup, H., Svendsen, K., Rasmussen, P. V., Ribe, L. R., Mikkelsen, I. K., Nagenthiraja, K., Cho, T.-H., Reding Tags: Emergency treatment of Stroke, Computerized tomography and Magnetic Resonance Imaging, Neuroprotectors, Thrombolysis Clinical Sciences Source Type: research

Alteplase for Acute Ischemic Stroke: Outcomes by Clinically Important Subgroups in the Third International Stroke Trial Clinical Sciences
Conclusions— Among the types of patient in the Third International Stroke Trial, this secondary analysis did not identify any subgroups for whom treatment should be avoided. Given the limitations of the analysis, we found no clear evidence to avoid treatment in patients with prior ischemic stroke, diabetes mellitus, or hypertension. Clinical Trial Registration— URL: http://www.controlled-trials.com. Unique identifier: ISRCTN25765518. http://www.controlled-trials.com/ISRCTN25765518.
Source: Stroke - February 23, 2015 Category: Neurology Authors: Lindley, R. I., Wardlaw, J. M., Whiteley, W. N., Cohen, G., Blackwell, L., Murray, G. D., Sandercock, P. A. G., on behalf of the IST-3 Collaborative Group, Trial Steering Committee, Baigent, Chadwick, Tyrrell, Lowe, Dennis, Innes, Goodare, CT and MR readi Tags: Acute Cerebral Infarction, Emergency treatment of Stroke, Thrombolysis Clinical Sciences Source Type: research

Vessel Wall Enhancement and Blood-Cerebrospinal Fluid Barrier Disruption After Mechanical Thrombectomy in Acute Ischemic Stroke Clinical Sciences
Conclusions—These findings may support the clinical relevance of direct vessel damage and BCSFB disruption after acute stroke and reinforce the need for further improvements in reperfusion strategies. Further validation in larger cohorts of patients is warranted.
Source: Stroke - February 26, 2017 Category: Neurology Authors: Arturo Renu, Carlos Laredo, Antonio Lopez–Rueda, Laura Llull, Raul Tudela, Luis San–Roman, Xabier Urra, Jordi Blasco, Juan Macho, Laura Oleaga, Angel Chamorro, Sergio Amaro Tags: Blood-Brain Barrier, Cerebrovascular Disease/Stroke, Ischemic Stroke Original Contributions Source Type: research

Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-Stroke Clinical Sciences
Conclusions—Hospital and eligibility delays such as delay diagnosis and inability to determine eligibility were associated with longer door-to-needle times. Improved stroke recognition and management of acute comorbidities may help to reduce door-to-needle times.
Source: Stroke - March 27, 2017 Category: Neurology Authors: Noreen Kamal, Shubin Sheng, Ying Xian, Roland Matsouaka, Michael D. Hill, Deepak L. Bhatt, Jeffrey L. Saver, Mathew J. Reeves, Gregg C. Fonarow, Lee H. Schwamm, Eric E. Smith Tags: Quality and Outcomes, Ischemic Stroke Original Contributions Source Type: research

Safety and Preliminary Efficacy of Early Tirofiban Treatment After Alteplase in Acute Ischemic Stroke Patients Brief Reports
Conclusions— Intravenous tirofiban immediately after alteplase seems to be safe and potentially more effective when compared with alteplase alone for selected stroke patients. Clinical Trial Registration— URL: http://www.chictr.org.cn/. Unique identifier: ChiCTR-TRC-14004630.
Source: Stroke - September 25, 2016 Category: Neurology Authors: Li, W., Lin, L., Zhang, M., Wu, Y., Liu, C., Li, X., Huang, S., Liang, C., Wang, Y., Chen, J., Feng, W. Tags: Pharmacology, Treatment, Ischemic Stroke Brief Reports Source Type: research

Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke Brief Reports
Conclusions— In patients with acute ischemic stroke, alteplase 0.9 mg/kg caused significant disruption of the fibrinolytic system, whereas tenecteplase 0.25 mg/kg did not, consistent with the trend toward lower intracerebral hemorrhage incidence with tenecteplase in the ATTEST study. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01472926.
Source: Stroke - November 23, 2015 Category: Neurology Authors: Huang, X., Moreton, F. C., Kalladka, D., Cheripelli, B. K., MacIsaac, R., Tait, R. C., Muir, K. W. Tags: Treatment, Ischemic Stroke, Thrombosis Brief Reports Source Type: research

Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke Brief Report
Background and Purpose—Renal dysfunction (RD) is associated with poor prognosis after stroke. We assessed the effects of RD on outcomes and interaction with low- versus standard-dose alteplase in a post hoc subgroup analysis of the ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study).Methods—A total of 3220 thrombolysis-eligible patients with acute ischemic stroke (mean age, 66.5 years; 37.8% women) were randomly assigned to low-dose (0.6 mg/kg) or standard-dose (0.9 mg/kg) intravenous alteplase within 4.5 hours of symptom onset. Six hundred and fifty-nine (19.8%) patients had moderate-to-severe R...
Source: Stroke - August 28, 2017 Category: Neurology Authors: Susan J. Carr, Xia Wang, Veronica V. Olavarria, Pablo M. Lavados, Jorge A. Rodriguez, Jong S. Kim, Tsong-Hai Lee, Richard I. Lindley, Octavio M. Pontes-Neto, Stefano Ricci, Shoichiro Sato, Vijay K. Sharma, Mark Woodward, John Chalmers, Craig S. Anderson, Tags: Clinical Studies, Intracranial Hemorrhage, Ischemic Stroke Brief Reports Source Type: research

Imaging Negative Stroke: Diagnoses and Outcomes in Intravenous Tissue Plasminogen Activator–Treated Patients
Conclusions: Because most INS patients were found to have NNCI, which may represent either transient ischemic attack or aborted stroke, and there were no intracerebral hemorrhages in the INS group, our data support the safety of administering IV t-PA to all patients in whom acute ischemic stroke is clinically suspected. We have demonstrated that NNCI patients and stroke mimics are common, and future larger scale prospective studies are required to delineate the true frequencies of each and to evaluate differences in outcomes.
Source: Journal of Stroke and Cerebrovascular Diseases - October 7, 2013 Category: Neurology Authors: Ilana Spokoyny, Rema Raman, Karin Ernstrom, Brett C. Meyer, Thomas M. Hemmen Tags: Original Articles Source Type: research

Lytic therapy and mechanical thrombecomty over tele-stroke, a comprehensive stroke center experience (P1.275)
Conclusions:Our study shows that our Tele stroke program had evolved over time to involve more sites throughout the state of South Carolina. Post IV tPA sICH was within the expected range.Disclosure: Dr. Al Kasab has nothing to disclose. Dr. Debenham has nothing to disclose. Dr. Jones has nothing to disclose. Dr. Holmstedt has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Kasab, S. A., Debenham, E., Jones, D. J., Holmstedt, C. A. Tags: Pre-Hospital Stroke, Tele-Stroke, and mHealth Source Type: research